Jade Biosciences, Inc.
JBIO
$8.03
$0.131.65%
NASDAQ
06/30/2025 | |||||
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 342.51% | ||||
Total Receivables | -- | ||||
Inventory | -- | ||||
Prepaid Expenses | 163.48% | ||||
Finance Division Loans and Leases Current | -- | ||||
Total Finance Division Other Current Assets | -- | ||||
Other Current Assets | -- | ||||
Total Current Assets | 339.78% | ||||
|
|||||
Total Current Assets | 339.78% | ||||
Net Property, Plant & Equipment | 20.78% | ||||
Long-term Investments | -- | ||||
Goodwill | -- | ||||
Total Other Intangibles | -- | ||||
Finance Div Loans & Leases LT | -- | ||||
Total Finance Div Other LT Assets | -- | ||||
Total Other Assets | -98.76% | ||||
Total Assets | 297.64% | ||||
|
|||||
Total Accounts Payable | 79.98% | ||||
Total Accrued Expenses | 6.93% | ||||
Short-term Debt | -- | ||||
Current Portion of Long-Term Debt/Capital Leases | -- | ||||
Finance Division Debt Current | -- | ||||
Total Finance Division Other Current Liabilities | 74.49% | ||||
Total Other Current Liabilities | 74.49% | ||||
Total Current Liabilities | 34.71% | ||||
|
|||||
Total Current Liabilities | 34.71% | ||||
Long-Term Debt | -- | ||||
Short-term Debt | -- | ||||
Capital Leases | 1.15% | ||||
Finance Division Debt Non Current | -- | ||||
Total Finance Division Other Non Current Liabilities | -- | ||||
Total Other Liabilities | -- | ||||
Total Liabilities | -83.97% | ||||
|
|||||
Common Stock & APIC | 19,366.54% | ||||
Retained Earnings | -37.74% | ||||
Treasury Stock & Other | -- | ||||
Total Common Equity | 341.36% | ||||
|
|||||
Preferred Stock Redeemable | -- | ||||
Preferred Stock Non Redeemable | -- | ||||
Preferred Stock Convertible | -- | ||||
Preferred Stock, Others | -- | ||||
Total Preferred Equity | -- | ||||
|
|||||
Total Common Equity | 341.36% | ||||
Total Preferred Equity | -- | ||||
Total Minority Interest | -- | ||||
Total Equity | 341.36% | ||||
|